2002 Update of recommendations for the use of chemotherapy and radiotherapy protectants: Clinical practice guidelines of the american society of clinical oncology

Journal of Clinical Oncology

Volumn 20, Issue 12, 2002, Pages 2895-2903

  Schuchter, Lynn M ^a   Hensley, Martee L ^a   Meropol, Neal J ^a   Winer, Eric P ^a  

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AMIFOSTINE; ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; MESNA; MITOXANTRONE; PACLITAXEL; PROTECTIVE AGENT; RADIOACTIVE IODINE; RAZOXANE; VINCRISTINE;

ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHEMOTHERAPY INDUCED EMESIS; CHILDHOOD CANCER; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG MONITORING; HEMORRHAGIC CYSTITIS; HIGH RISK PATIENT; HUMAN; HYPOTENSION; LUNG SMALL CELL CANCER; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION INJURY; RADIATION PROTECTION; REVIEW; THROMBOCYTOPENIA; THYROID CANCER; URINARY TRACT DISEASE; XEROSTOMIA;

AMIFOSTINE; ANTINEOPLASTIC AGENTS; CHELATING AGENTS; HUMANS; MESNA; NEOPLASMS; PROTECTIVE AGENTS; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY; RAZOXANE;

EID: 0037096826     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.04.178     Document Type: Review

References (28)

1. American Society of Clinical Oncology: Clinical Practice Guidelines for the use of chemotherapy and radiotherapy protectants
2. Pharmacokinetics of an intravenous-oral versus intravenous mesna regimen in lung cancer patients receiving ifosfamide
3. Comparison of the efficacy and tolerability of intravenous and intravenous/oral mesna: A randomized controlled multi-center phase III trial with mesna tablets
4. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy
5. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer: The Provincial Systemic Treatment Disease Site Group
6. A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer
7. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer
8. Advanced small cell lung cancer treated with CAV (cyclophosphamide, Adriamycin + vincristine) chemotherapy and the cardioprotective agent dexrazoxane (ADR529, ICRF187. Zinecard)
9. Randomized trial of the cardioprotective agent ICRF- 187 in pediatric sarcoma patients treated with doxorubicin
10. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas
11. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer
12. Epirubicin cardiotoxicity: A study of 135 patients with advanced breast cancer
13. Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer
14. Epirubicin-based chemotherapy in metastatic breast cancer: Role of dose-intensity and duration of treatment
15. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: Role of cardiac risk factors
16. Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients
17. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer
18. Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy
19. High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer
20. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer
21. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer
22. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer
23. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer
24. Salivary gland protection by amifostine in high-dose radioiodine treatment: Results of a double blind placebo controlled study
25. Protective effect of amifostine on dental health after radiotherapy of the head and neck
26. Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study
27. A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck cancer
28. A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma